|
WASHINGTON, Nov. 23 /PRNewswire/ -- "We applaud the results of a research
study on the effectiveness of mycophenolate mofetil (MMF) as a potential new
treatment for lupus nephritis (lupus kidney disease) which are published in
the November 24, 2005 issue of the New England Journal of Medicine. The
multi-center clinical study found that MMF, or CellCept(R), was more effective
than the current standard-of-treatment with intravenous cyclophosphamide, and
had a better safety profile.
CellCept holds the promise of a better quality of life for people with
lupus who suffer the debilitating effects of severe lupus kidney disease.
Current chemotherapy drugs used to treat lupus nephritis have potentially
serious and life threatening side effects that can be worse than the primary
disease. It has been more than 30 years since the FDA has approved a new
therapy for lupus.
The results of this study are encouraging and offer hope that doctors soon
will have a safer and more effective treatment alternative that has fewer side
effects typically associated with currently-available treatments. Doctors and
their lupus patients eagerly await approval of CellCept as a new treatment
that will bring lupus under control and allow those affected to look forward
to a healthier future."
|
|
